p73β Inhibitors
p73β inhibitors represent a specific class of chemical compounds targeting the p73β protein, a member of the p53 family of transcription factors. The p73 gene plays a crucial role in regulating various cellular processes, including apoptosis, cell cycle progression, and DNA damage response. While p73 is often studied for its tumor-suppressing functions similar to p53, the isoform p73β has distinct regulatory capabilities that contribute to cellular signaling pathways. By modulating the activity of p73β, researchers can explore the underlying mechanisms of cellular responses to stress and the maintenance of genomic integrity.
Inhibitors of p73β provide valuable tools for investigating the functional dynamics of this protein and its interactions within the larger framework of the p53 family. The inhibition of p73β can lead to an altered expression of target genes involved in cell cycle regulation and apoptosis, facilitating studies on how cells manage stress and decide between survival and programmed cell death. This class of inhibitors can also help elucidate the complex interplay between various signaling pathways that converge on p73β, providing insights into its role in cellular differentiation and development. Additionally, understanding the modulation of p73β activity through these inhibitors can shed light on the broader implications of p73 in oncogenesis and tumor progression, thereby contributing to a more comprehensive knowledge of cellular biology and the regulatory networks involved in maintaining cellular homeostasis. Overall, p73β inhibitors are essential for advancing the study of cellular responses and the intricate balance of signaling pathways governed by p53 family proteins.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 may promote the stabilization and activation of p73 by disrupting its interaction with MDM2, potentially creating a feedback loop that downregulates p73β expression due to enhanced p73β activity. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Tozasertib, by inhibiting Aurora kinases, may disrupt cell cycle checkpoints, leading to an aberrant cell cycle that could consequentially decrease p73β expression due to altered cellular stress responses. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib, by inhibiting PARP enzymes, may reduce the transcriptional activity of genes involved in the DNA damage response, potentially leading to a decrease in p73β expression as part of the cellular adaptation to impaired DNA repair. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 blocks proteasomal degradation, potentially causing the accumulation of ubiquitinated proteins, which may lead to reduced transcription of certain stress response genes, including downregulation of p73β. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid could lead to histone hyperacetylation and consequent transcriptional repression of specific genes, possibly including the gene encoding p73β, thereby reducing its expression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a RAF kinase inhibitor, may disrupt downstream MEK-ERK signaling, leading to altered transcriptional programs that could include the downregulation of p73β expression as a secondary effect. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib may induce a cellular stress response that could cause a reprogramming of gene expression profiles, potentially targeting the transcriptional machinery to decrease p73β expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for cap-dependent translation, potentially leading to selective translational repression of mRNAs, including those encoding p73β. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide can prompt the degradation of transcription factors via the E3 ubiquitin ligase complex, possibly resulting in diminished p73β mRNA synthesis and hence reduced protein expression. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib selectively inhibits certain tyrosine kinases, which may result in the deactivation of transcription factors and a subsequent decrease in the expression levels of their target genes, one of which could be p73β. | ||||||